Clinical Trial Search

Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas

Primary: Clinical Efficacy: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline — 51.29; 26.63; 21.82 percentage…

Primary: Percentage of BCCs With Complete and at Least Partial Clinical Clearance — 92; 7; 83; 77 Percentage of BCCs

Primary: Number of New Surgically Eligible Basal-cell Carcinomas — 34; 2 events per patient year

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated — -26.8 percentage size change from baseline

Primary: Mohs Micrographic Surgery (MMS) — 1 mm

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale

Primary: Percentage of Participants With Complete Histologic Clearance — 42.0; 16.0; 44.0 Percentage of participants — p=0.8463

Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage

Primary: Number of Treatment-emergent Adverse Events (Including Both Serious and Non-Serious) Causally Related to Study Drug — 0; 0; 0; 2 number of events

Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04

Primary: Complete Response Rate — 2 Participants

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants

Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors

Primary: Tumor Clearance Rate Following Red or Blue Light PDT — 87.3; 99 Percentage of tumors cleared

Primary: Objective Response (OR) Determined by the Independent Review Facility — 30.3; 42.9 Percentage of participants — p=0.0011

Primary: Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter — 5; 29 participants

Primary: Mean Percent Change From Baseline in the Number of Clinically Evident Basal Cell Carcinomas at Week 73 (After 72 Weeks of Treatment) — 62.9; 54.9 percent change

Primary: Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs) — 3; 0; 3; 0 Participants

Primary: Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell…

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…

Primary: Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse…

Primary: Determination of RP2D — 1000 mg

Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants

Primary: Percentage of Lesions Cleared Histologically — 3; 5 Lesion

Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease

Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions

Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants